JP2008502355A5 - - Google Patents

Download PDF

Info

Publication number
JP2008502355A5
JP2008502355A5 JP2007526437A JP2007526437A JP2008502355A5 JP 2008502355 A5 JP2008502355 A5 JP 2008502355A5 JP 2007526437 A JP2007526437 A JP 2007526437A JP 2007526437 A JP2007526437 A JP 2007526437A JP 2008502355 A5 JP2008502355 A5 JP 2008502355A5
Authority
JP
Japan
Prior art keywords
agent
group
polypeptide
ecm
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007526437A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008502355A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/052754 external-priority patent/WO2005121778A2/en
Publication of JP2008502355A publication Critical patent/JP2008502355A/ja
Publication of JP2008502355A5 publication Critical patent/JP2008502355A5/ja
Pending legal-status Critical Current

Links

JP2007526437A 2004-06-14 2005-06-14 変性性及び炎症性疾患の治療に役立つ同定方法及び化合物 Pending JP2008502355A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57930704P 2004-06-14 2004-06-14
PCT/EP2005/052754 WO2005121778A2 (en) 2004-06-14 2005-06-14 Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases

Publications (2)

Publication Number Publication Date
JP2008502355A JP2008502355A (ja) 2008-01-31
JP2008502355A5 true JP2008502355A5 (https=) 2009-04-30

Family

ID=35503767

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007526437A Pending JP2008502355A (ja) 2004-06-14 2005-06-14 変性性及び炎症性疾患の治療に役立つ同定方法及び化合物

Country Status (7)

Country Link
US (3) US7306923B2 (https=)
EP (4) EP2256198A1 (https=)
JP (1) JP2008502355A (https=)
AT (1) ATE534736T1 (https=)
CA (1) CA2569511A1 (https=)
MX (1) MXPA06014577A (https=)
WO (1) WO2005121778A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485468B2 (en) * 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
CN103173401A (zh) * 2005-12-22 2013-06-26 简·恩尼斯 来自冷冻的脐带组织的活细胞
WO2008155397A2 (en) 2007-06-20 2008-12-24 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
CN101970012A (zh) 2007-09-14 2011-02-09 日东电工株式会社 药物载体
US8450397B2 (en) * 2007-09-25 2013-05-28 Dunlop Sports Co. Ltd. Golf ball
DE102007059839A1 (de) 2007-12-11 2009-06-25 Harald Dipl.-Ing. Feuerherm Schlauchförmiger Vorformling und Herstellung blasgeformter Teile und Verfahren sowie Vorrichtung zur Herstellung des Vorformlings
ES2690348T3 (es) * 2008-09-24 2018-11-20 Tel Hashomer Medical Research Infrastructure And Services Ltd. Péptidos y composiciones para la prevención de la adhesión celular y métodos de uso de los mismos
US8552147B2 (en) * 2008-12-29 2013-10-08 Tel Hashomer Medical Research, Infrastructure And Services Ltd. Peptides and compositions for prevention of cell adhesion and methods of using same
US11174299B2 (en) 2008-12-29 2021-11-16 Dispersebio Ltd. Peptides and compositions for prevention of cell adhesion and methods of using same
AU2015224504B2 (en) * 2008-12-29 2018-02-22 Tel Hashomer Medical Research, Infrastructure And Services Ltd Peptides and compositions for prevention of cell adhesion and methods of using same
US8663930B2 (en) * 2009-04-01 2014-03-04 Galapagos Nv Methods and means for treatment of osteoarthritis
EP2812028A4 (en) 2012-02-07 2016-01-06 Jolla Inst Allergy Immunolog EPITOPES OF ALLERGENIC PROTEINS AND METHOD AND USE TO IMMUNE REACTION MODULATION
US20160138027A1 (en) * 2013-03-14 2016-05-19 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
EP3682034A1 (en) * 2017-09-13 2020-07-22 Alexera AB Methods for identifying therapeutic agents which interact with stk24
EP4090371A4 (en) * 2020-01-14 2024-04-03 The Trustees of Columbia University in the City of New York Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
WO1999038980A2 (en) 1998-01-29 1999-08-05 The Board Of Regents Of The University Of Oklahoma Tyrosylprotein sulfotransferase polypeptides and polynucleotides
WO2000014250A1 (en) 1998-09-09 2000-03-16 The Board Of Regents Of The University Of Oklahoma Tyrosylprotein sulfotransferase polypeptides and polynucleotides
WO1999041364A2 (en) * 1998-02-13 1999-08-19 The Wistar Institute Compositions and methods for wound healing
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20020151681A1 (en) * 1999-03-12 2002-10-17 Rosen Craig A. Nucleic acids, proteins and antibodies
US20050112118A1 (en) * 1999-12-02 2005-05-26 Myriad Genetics, Incorporated Compositions and methods for treating inflammatory disorders
US7332337B2 (en) 2000-05-16 2008-02-19 Galapagos Nv Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
US20020132823A1 (en) 2001-01-17 2002-09-19 Jiahuai Han Assay method
WO2002070744A2 (en) 2001-03-07 2002-09-12 Galapagos Genomics B.V. Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds
US6537780B2 (en) 2001-03-28 2003-03-25 Applera Corporation Isolated nucleic acid molecules encoding transferase enzymes
US6426221B1 (en) * 2001-08-01 2002-07-30 Isis Pharmaceuticals, Inc. Antisense modulation of RIP2 expression
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
WO2003065006A2 (en) * 2002-01-31 2003-08-07 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
US20070010434A1 (en) * 2002-09-16 2007-01-11 Genetech, Inc. Novel compositions and methods for the treatment of immune related diseases
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
EP1578367A4 (en) * 2002-11-01 2012-05-02 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
AU2004205785A1 (en) * 2003-01-23 2004-08-05 Eirx Therapeutics Limited Kinases and GPCRs involved in apoptosis
EP1618209A2 (en) * 2003-04-18 2006-01-25 Novartis AG High throughput functional genomic screening methods for osteoarthritis
WO2004094636A1 (en) 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs
DE10328033A1 (de) 2003-06-19 2005-01-05 Bläß, Stefan, Dr. Verfahren und ArthritisChip zur Diagnostik, Verlaufskontrolle sowie zur Charakterisierung der rheumatoiden Arthritis und der Osteoarthrose
WO2005012875A2 (en) * 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
US7485468B2 (en) * 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases

Similar Documents

Publication Publication Date Title
JP2008516593A5 (https=)
JP7079761B2 (ja) 心不全の治療のための標的としてのｂａｇ３
JP2008502355A5 (https=)
JP2008503712A5 (https=)
JP2007534725A5 (https=)
JP6437467B2 (ja) 線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法
JP2011515653A (ja) 神経変性疾患の治療に有用な標的配列及びそれらの同定方法
US8663936B2 (en) Sodium channel protein type III α-subunit splice variant
JP2016522675A (ja) 上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター
US7125676B2 (en) Expression system for human brain-specific voltage-gated sodium channel, type 1
JP2012517822A (ja) 炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物
WO2005121778B1 (en) Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
EP2210112A1 (en) Diagnostic methods for hiv infection
JP2019524740A (ja) Ｃｒｅｂｂｐ関連癌の治療法
JP2005507648A5 (https=)
JP7177439B2 (ja) 炎症促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法
JP2007533989A5 (https=)
JP7175526B2 (ja) 細胞遊走調節に関する疾患の予防・治療剤および肺間質の疾患の疾患活動性判定・予後評価
US20110077283A1 (en) Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2016170022A1 (en) Therapeutic methods, products and compositions inhibiting znf555
EP2795337B1 (en) Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions
JP2016518812A (ja) 線維症治療において有用な分子標的及び前記標的のインヒビター
CA2737549A1 (en) Compositions and methods for modulating toll-like receptor activity
US20100284968A1 (en) Use of PS20/WFDC1 and Interferons to Diagnose, Monitor and Treat Viral Diseases
JP7325075B2 (ja) フリズルド３発現細胞の細胞数増加剤若しくは低下剤、糖尿病予防若しくは治療剤、インスリノーマ予防若しくは治療剤、及びインスリン分泌促進剤若しくは分泌抑制剤よりなる群から選択される少なくとも１つの剤をスクリーニングするためのスクリーニング剤、スクリーニング用キット、及びスクリーニング方法